L R Luckett-Chastain1, R M Gallucci. 1. Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma, Health Sciences Center, Oklahoma City, OK 73117, USA
Abstract
BACKGROUND: Interleukin (IL-6) and transforming growth factor (TGF)-beta have been shown to play a role in skin development and maintenance. OBJECTIVES: A link between these two cytokines has yet to be identified and therefore in this study we investigated the modulation of TGF-beta1 and TGF-beta type 2 receptor (TGF-betaR2) by IL-6 in skin. METHODS: An IL-6 knockout (IL-6KO) fibroblast-populated lattice model and intradermal injections of IL-6 into unwounded IL-6KO mice were used to investigate the direct effects of IL-6 treatment on TGF-beta and TGF-betaR2 expression and to determine the signalling mechanism. In addition, IL-6KO and C57BL/6 control mice were wounded by a 4-mm punch biopsy to monitor expression of TGF-beta1 and TGF-betaR2 within a wound over time. The expression of TGF-beta1 and TGF-betaR2 was assessed by real-time quantitative polymerase chain reaction, enzyme-linked immunosorbent assay and immunohistology. RESULTS: Recombinant IL-6 treatment of IL-6KO lattices and intradermal injections of IL-6 showed a significant induction of TGF-beta1 mRNA and protein, with TGF-beta1 expression localized in the dermis, while TGF-betaR2 expression was primarily in the epidermis in IL-6KO mice. During healing, the expression of TGF-beta1 and TGF-betaR2 mRNA was significantly greater in unwounded and 7-day-old wounds from wild-type mice; however, protein expression did not differ. Treatment with signal transduction inhibitors indicated that IL-6 modulates TGF-beta through a mitogen-activated protein kinase/extracellular signal-regulated kinase (Mapk/Erk)-dependent mechanism. CONCLUSION: These studies indicate that IL-6 has the ability to modulate the expression of TGF-beta and TGF-betaR2 to varying degrees in the skin, which may provide a possible mechanism for defining the role of IL-6 in skin maintenance and a new association of IL-6 with TGF-beta in pathologies associated with fibrosis.
BACKGROUND: Interleukin (IL-6) and transforming growth factor (TGF)-beta have been shown to play a role in skin development and maintenance. OBJECTIVES: A link between these two cytokines has yet to be identified and therefore in this study we investigated the modulation of TGF-beta1 and TGF-beta type 2 receptor (TGF-betaR2) by IL-6 in skin. METHODS: An IL-6 knockout (IL-6KO) fibroblast-populated lattice model and intradermal injections of IL-6 into unwounded IL-6KO mice were used to investigate the direct effects of IL-6 treatment on TGF-beta and TGF-betaR2 expression and to determine the signalling mechanism. In addition, IL-6KO and C57BL/6 control mice were wounded by a 4-mm punch biopsy to monitor expression of TGF-beta1 and TGF-betaR2 within a wound over time. The expression of TGF-beta1 and TGF-betaR2 was assessed by real-time quantitative polymerase chain reaction, enzyme-linked immunosorbent assay and immunohistology. RESULTS: Recombinant IL-6 treatment of IL-6KO lattices and intradermal injections of IL-6 showed a significant induction of TGF-beta1 mRNA and protein, with TGF-beta1 expression localized in the dermis, while TGF-betaR2 expression was primarily in the epidermis in IL-6KO mice. During healing, the expression of TGF-beta1 and TGF-betaR2 mRNA was significantly greater in unwounded and 7-day-old wounds from wild-type mice; however, protein expression did not differ. Treatment with signal transduction inhibitors indicated that IL-6 modulates TGF-beta through a mitogen-activated protein kinase/extracellular signal-regulated kinase (Mapk/Erk)-dependent mechanism. CONCLUSION: These studies indicate that IL-6 has the ability to modulate the expression of TGF-beta and TGF-betaR2 to varying degrees in the skin, which may provide a possible mechanism for defining the role of IL-6 in skin maintenance and a new association of IL-6 with TGF-beta in pathologies associated with fibrosis.
Authors: Sun Young Lee; Jae Woong Lee; Heesoon Lee; Han Soo Yoo; Yeo Pyo Yun; Ki Wan Oh; Tae Youl Ha; Jin Tae Hong Journal: Brain Res Mol Brain Res Date: 2005-09-08
Authors: Lerin R Luckett-Chastain; Mackenzie L Cottrell; Bethany M Kawar; Michael A Ihnat; Randle M Gallucci Journal: Exp Dermatol Date: 2017-03-08 Impact factor: 3.960
Authors: Matthias Zenkel; Piotr Lewczuk; Anselm Jünemann; Friedrich E Kruse; Gottfried O H Naumann; Ursula Schlötzer-Schrehardt Journal: Am J Pathol Date: 2010-04-15 Impact factor: 4.307
Authors: Moumita Rakshit; Archana Gautam; Li Zhen Toh; Ying Shi Lee; Hui Ying Lai; Tina T Wong; Kee Woei Ng Journal: Int J Nanomedicine Date: 2020-07-13
Authors: Michael L Freeman; Carey L Shive; Thao P Nguyen; Souheil-Antoine Younes; Soumya Panigrahi; Michael M Lederman Journal: J Infect Dis Date: 2016-10-01 Impact factor: 5.226
Authors: Olga Rassouli; George Liapakis; Iakovos Lazaridis; George Sakellaris; Kostas Gkountelias; Achille Gravanis; Andrew N Margioris; Katia P Karalis; Maria Venihaki Journal: PLoS One Date: 2011-07-13 Impact factor: 3.240